GALT

Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update

Galectin Therapeutics to Present at 4th Global NASH Congress

Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be Delivered

GALT Stock: Over 25% Increase Pre-Market Explanation

Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics' Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy